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Introduction
Since the molecular cloning of natural killer (NK) receptors was achieved in 1995, [1] [2] [3] it has subsequently been shown that these receptors, which are now called killer cell immunoglobulin-like receptors (KIRs), transmit positive and/or negative signals. 4, 5 It is now widely accepted that the expression of KIRs is involved in the cytolytic function of NK cells, as demonstrated by a number of studies focusing on these receptors. 6, 7 Analysis of KIR expression has contributed to revealing the regulation and function of NK cell activation.
Interleukin (IL)-15 was discovered in 1994 and shown to have the potential to enhance cell-mediated immune responses to intracellular pathogens and tumors. 8, 9 IL-15 shares no homology with IL-2, but IL-15 shares many of the biologic activities of IL-2, including induction of the proliferation of phytohemagglutinin-stimulated normal peripheral blood mononuclear cells (PBMC), NK cells, B cells, and T cells, and generation of allogenic cytotoxic T lymphocytes in vitro. [8] [9] [10] [11] [12] [13] Although IL-2 and IL-15 are lymphocyte growth factors with overlapping functions in immune responses, the cells that produce IL-15 are different from those that produce IL-2. IL-2 is produced by activated T cells, while in contrast IL-15 is produced by epithelial cells and macrophages, which range over the whole body. 8 Thus, it is considered that IL-15 maintains T cells, diminishes the occurrence of malignant tumors and defends against microbial infections, and that these actions are partly due to the enhancement of the function of NK cells by IL-15. Indeed, IL-15 is an essential regulator of the differentiation of NK cells from stem cells, 14 -16 and moreover IL-15 can stimulate or augment the activation of mature human NK cells. 17 However, little is known about the effects of IL-15 on the expression of NK receptors, which are involved in NK cell regulation.
The aim of the present study was to assess the effect of IL-15 on the expression of KIRs on mature NK cells (CD16 + ) and CD8 + T cells to clarify the mechanism of NK cell regulation by IL-15.
Methods

Reagents
Fluorescein isothiocyanate (FITC)-conjugated antihuman CD8, FITC-anti-human CD16, phycoerythrin (PE)-conjugated anti-human CD158a and PE-conjugated anti-human CD158b were purchased from Immunotech (Marseille, France). Recombinant human IL-2 was obtained from Pharmabiotechnology (Hannover, Germany). Recombinant human IL-15 was purchased from Strathmann Biotech (Hamburg, Germany).
Cells
PBMC obtained from 10 healthy subjects were separated from heparinized blood by Lymphoprep (Nyegaard, Oslo, Norway) gradient cenfugation. 18 Each PBMC sample was incubated in a culture dish in a humidified 5% CO 2 /95% air atmosphere at 37°C for 60 min. After the incubation, non-adherent cells were collected and washed twice in phosphate-buffered saline.
Cell culture
One million cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (Biological Industries, Israel) in tissue culture dishes (Becton Dickinson, Franklin, NJ, USA). The cell cultures were incubated in medium only or medium supplemented with IL-2 at 100 U/ml or IL-15 at 0.1, 1.0, or 10.0 ng/ml in a humidified 5% CO 2 /95% air atmosphere at 37°C for 48 h. After each incubation, cells were collected and their surface antigens were analyzed using flow cytometry (Epics XL; Beckman Coulter, France). Each experiment was carried out in duplicate.
Cell phenotype
Surface phenotyping was carried out using a twocolor immunofluorescence staining technique, with isotype-specific mouse anti-human antibody conjugated with either FITC or PE. 19 Each sample of stained cells was suspended in 0.5 ml of phosphate-buffered saline and analyzed by flow cytometry. Lymphocyte subsets were identified by gating analysis, and fluorescence profiles were obtained for 10,000 cells of each sample. Negative controls for each experiment were performed with FITC-and PE-labeled mouse immunoglobulin G.
NK cytolytic activity
NK activity was assessed against K562, a myelogenous leukemia cell line, in a 3-h 51 Cr-release assay as described previously. The effector cells were mixed with labeled target cells at various cell concentrations to give an effector-to-target ratio of 20:1 or 10:1. Duplicate samples were prepared for each ratio. The supernatants were withdrawn after a 4-h incubation period, and the 51 Cr released from lysed target cells was quantitated in a gamma counter (Packard Instrument Co., Boston, MA, USA). Incubation of target cells with medium or saponin (7 mg/ml) and ethylenediamine tetraacetic acid (0.1 mg/ml) was used to determine spontaneous and maximal release, respectively. The percent cytotoxicity was calculated by the formula: (cpm of effector cells -cpm of spontaneous release)/(cpm of maximal release -cpm of spontaneous release) ´100.
Statistical analysis
Data are expressed as mean (standard deviation) values. All data were collected in a computer database and analyzed using the StatView-J 4.02 program (Abacus Concept, Berkeley, CA, USA). The Wilcoxon signed-rank test was performed for each set of data for NK activity and surface antigen expression. For all statistical tests, differences were regarded as statistically significant at p<0.05.
Results
Enhancement of NK cytolytic activity by IL-15
To confirm the ability of IL-15 to elevate the natural killing activity, we measured the NK activity after incubation (48 h) with IL-15 (concentration, 0.1, 1.0, or 10.0 ng/ml). The results are presented in Table 1 . At 0.1 ng/ml of IL-15, the NK activity was significantly increased compared with medium alone. The increase of NK cytolytic activity by treatment with IL-15 was Mediators of Inflammation · Vol 11 · 2002 dose dependent from 0.1 to 10 ng/ml. The effect of 1.0 ng/ml of IL-15 was similar to that of 100 U/ml of IL-2, and 10 ng/ml of IL-15 significantly elevated the NK activity compared with 100 U/ml of IL-2.
Expansion of the CD16 + CD158a/b + cell population by IL-15
The signals from KIRs play a crucial role in NK cell regulation, and therefore we investigated the populations of CD158a-positive and CD158b-positive cells.
IL-15 at 1.0 ng/ml expanded the population of CD16 + CD158a + cells significantly, and this effect was nearly to equal to that of 100 U/ml of IL-2 (Fig. 1) . The expansion of CD16 + CD158a + cells by treatment with IL-15 was dose dependent from 0.1 to 10 ng/ml. IL-15 also expanded the population of CD16 + CD158b + cells, but the effect of 10 ng/ml of IL-15 was not different from that of 1.0 ng/ml of IL-15 or 100 U/ml of IL-2 (Fig. 1) . contrast, the total populations of CD8 + cells and CD16 + cells were not changed by treatment with IL-15 (data not shown).
In addition, we further analyzed the change in the expression per cell of KIRs in response to IL-15. The representative data was shown in Fig. 2 . The CD158b molecule on each lymphocyte were upregulated. 20, 21 In the present study, the population of CD8 + cells was not expanded by the treatment with IL-15. Instead, the population of activated T lymphocytes probably increased.
As for NK cells, the proliferation, survival, and effector functions of resting NK cells are induced by exogeneous IL-15. 9, 17 In vitro, IL-15 induces the cytotoxic activity of NK cells as well as T cells. 15, 22 Our data also demonstrated that IL-15 enhances NK activity. Although the degree of its ability to enhance the NK activity varies depending on the report, it appeared to be more effective than IL-2 in the present study. The biological functions of IL-15 are similar to
The change of the KIRs expression per cell in response to IL-15. Representative data using PE-labeled CD158b was shown. Upper panel, medium alone; lower panel, medium with 10 ng/ml of IL-15. The population of CD158b-positive cell was 8.7% in medium alone, and 9.7% under the condition in medium with 10 ng/ml of IL-15. Especially, the intensity of PE was higher in medium with 10 ng/ml of IL-15 than in medium alone. These phenomena indicated that the CD158b molecule on each lymphocyte was upregulated. It is now widely accepted that NK cells recognize and lyse target cells through the interplay of two families of receptors. 24 -26 One family consists of killer-cell activating receptors such as CD69 27 and 2B4, 28 and the other consists of KIRs. The activating signal can be over-ridden by a dominant-negative signal from a KIR when the KIR interacts with its ligand on the target cell, although activating receptors, when occupied, trigger lysis of the target cell being recognized. Recently, it has been reported that KIR downregulation on NK cells is associated with the downregulation of activating receptors, 29 + cells were dose dependent from 0.1 to 10 ng/ml, as was the increase of NK cytolytic activity by treatment with IL-15. In contrast, while the expansions of the CD158b + cell population was dose dependent from 0.1 to 1.0 ng/ ml, there was no significant difference between the effect of 10 ng/ml and that of 1.0 ng/ml. We considered that further expansion of CD158b + cells did not occur despite the increase of NK activity by 10 ng/ml compared with 1.0 ng/ml because the NK activity is dependent on several signals from NK receptors. However, it is difficult to explain the difference between the responses of the CD158a and CD158b molecules. The possible shared functions of the CD158a and CD158b molecules are still not known, although it is well known that their ligands are different.
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